Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
AGN's Cash to Debt is ranked lower than
94% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. AGN: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
AGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.54 Max: 43.62
Current: 0.05
0.02
43.62
Equity to Asset 0.54
AGN's Equity to Asset is ranked lower than
62% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. AGN: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
AGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.62 Max: 0.93
Current: 0.54
0.25
0.93
F-Score: 6
Z-Score: 1.24
M-Score: -1.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -7.16
AGN's Operating margin (%) is ranked lower than
82% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. AGN: -7.16 )
Ranked among companies with meaningful Operating margin (%) only.
AGN' s Operating margin (%) Range Over the Past 10 Years
Min: -21.33  Med: 9.40 Max: 14.13
Current: -7.16
-21.33
14.13
Net-margin (%) 16.71
AGN's Net-margin (%) is ranked higher than
87% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. AGN: 16.71 )
Ranked among companies with meaningful Net-margin (%) only.
AGN' s Net-margin (%) Range Over the Past 10 Years
Min: -22.48  Med: 5.41 Max: 9.4
Current: 16.71
-22.48
9.4
ROE (%) 6.56
AGN's ROE (%) is ranked lower than
52% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. AGN: 6.56 )
Ranked among companies with meaningful ROE (%) only.
AGN' s ROE (%) Range Over the Past 10 Years
Min: -23.54  Med: 6.12 Max: 12.05
Current: 6.56
-23.54
12.05
ROA (%) 3.62
AGN's ROA (%) is ranked higher than
50% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. AGN: 3.62 )
Ranked among companies with meaningful ROA (%) only.
AGN' s ROA (%) Range Over the Past 10 Years
Min: -13.02  Med: 3.54 Max: 6.67
Current: 3.62
-13.02
6.67
ROC (Joel Greenblatt) (%) -33.25
AGN's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. AGN: -33.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -37.89  Med: 22.90 Max: 39.38
Current: -33.25
-37.89
39.38
Revenue Growth (3Y)(%) 17.90
AGN's Revenue Growth (3Y)(%) is ranked higher than
79% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. AGN: 17.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.4  Med: 17.55 Max: 40.5
Current: 17.9
6.4
40.5
EBITDA Growth (3Y)(%) -3.70
AGN's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. AGN: -3.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.4  Med: 5.60 Max: 33.2
Current: -3.7
-4.4
33.2
» AGN's 10-Y Financials

Financials (Next Earnings Date: 2016-02-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AGN Guru Trades in Q1 2015

Steve Mandel 1,832,314 sh (New)
Bill Ackman 1,348,358 sh (New)
Ken Fisher 3,233 sh (New)
Lee Ainslie 316,188 sh (New)
Julian Robertson 72,500 sh (New)
Signature Select Canadian Fund 10,600 sh (New)
Pioneer Investments 592,904 sh (+517.20%)
Louis Moore Bacon 31,216 sh (+307.20%)
John Paulson 5,640,788 sh (+261.45%)
Steven Cohen 3,783 sh (+152.20%)
Diamond Hill Capital 4,100 sh (+38.23%)
First Eagle Investment 1,573,572 sh (+33.74%)
Andreas Halvorsen 6,105,536 sh (+33.14%)
Mario Gabelli 35,151 sh (+30.72%)
George Soros 417,367 sh (+29.93%)
Larry Robbins 1,982,709 sh (+7.65%)
Daniel Loeb 3,575,000 sh (+3.62%)
Vanguard Health Care Fund 9,038,107 sh (+2.75%)
Bernard Horn 20,689 sh (unchged)
Jim Simons Sold Out
Daniel Loeb Sold Out
First Eagle Investment Sold Out
Jim Simons Sold Out
Ken Fisher Sold Out
Mario Gabelli Sold Out
Pioneer Investments Sold Out
Louis Moore Bacon Sold Out
Eric Mindich Sold Out
George Soros Sold Out
Andreas Halvorsen Sold Out
Paul Singer Sold Out
Joel Greenblatt Sold Out
Larry Robbins Sold Out
Steven Cohen Sold Out
Eric Mindich Sold Out
John Paulson Sold Out
Bill Ackman Sold Out
Paul Tudor Jones Sold Out
Leon Cooperman 933,475 sh (-1.07%)
Scott Black 39,451 sh (-3.99%)
Private Capital 158,852 sh (-4.42%)
Jana Partners 1,621,852 sh (-5.64%)
RS Investment Management 385,566 sh (-6.87%)
John Griffin 1,466,000 sh (-9.78%)
Paul Tudor Jones 2,200 sh (-18.52%)
Dodge & Cox 1,602 sh (-51.35%)
Jeremy Grantham 263,619 sh (-82.00%)
» More
Q2 2015

AGN Guru Trades in Q2 2015

John Burbank 249,857 sh (New)
Louis Moore Bacon 19,346 sh (New)
Chris Davis 2,100 sh (New)
Howard Marks 71,000 sh (New)
Alan Fournier 220,000 sh (New)
John Keeley 660 sh (New)
Lee Ainslie 1,459,560 sh (+361.61%)
Paul Tudor Jones 5,937 sh (+169.86%)
John Paulson 7,174,200 sh (+27.18%)
Steve Mandel 2,297,966 sh (+25.41%)
Pioneer Investments 711,397 sh (+19.99%)
Diamond Hill Capital 4,890 sh (+19.27%)
Andreas Halvorsen 6,804,034 sh (+11.44%)
Ken Fisher 3,580 sh (+10.73%)
RS Investment Management 415,082 sh (+7.66%)
Mario Gabelli 37,286 sh (+6.07%)
Private Capital 165,927 sh (+4.45%)
Vanguard Health Care Fund 9,038,107 sh (unchged)
John Griffin 1,466,000 sh (unchged)
Larry Robbins 1,982,709 sh (unchged)
Bernard Horn 20,689 sh (unchged)
Steven Cohen Sold Out
Bill Ackman Sold Out
Dodge & Cox 1,601 sh (-0.06%)
Jana Partners 1,618,385 sh (-0.21%)
Scott Black 39,110 sh (-0.86%)
Leon Cooperman 922,375 sh (-1.19%)
First Eagle Investment 1,546,324 sh (-1.73%)
Daniel Loeb 3,300,000 sh (-7.69%)
Julian Robertson 44,500 sh (-38.62%)
George Soros 159,338 sh (-61.82%)
Jeremy Grantham 1,029 sh (-99.61%)
» More
Q3 2015

AGN Guru Trades in Q3 2015

Paul Singer 663,000 sh (New)
Ruane Cunniff 1,103,395 sh (New)
Kyle Bass 17,813 sh (New)
Wallace Weitz 187,607 sh (New)
Jim Simons 53,969 sh (New)
First Pacific Advisors 30,580 sh (New)
Jeremy Grantham 819,684 sh (+79558.31%)
Diamond Hill Capital 66,793 sh (+1265.91%)
George Soros 774,566 sh (+386.12%)
Signature Select Canadian Fund 35,400 sh (+233.96%)
Alan Fournier 652,100 sh (+196.41%)
Paul Tudor Jones 11,317 sh (+90.62%)
Julian Robertson 59,700 sh (+34.16%)
Jana Partners 1,886,931 sh (+16.59%)
Steve Mandel 2,607,655 sh (+13.48%)
John Griffin 1,630,842 sh (+11.24%)
Daniel Loeb 3,669,000 sh (+11.18%)
First Eagle Investment 1,671,156 sh (+8.07%)
Andreas Halvorsen 7,202,384 sh (+5.85%)
Private Capital 169,620 sh (+2.23%)
Vanguard Health Care Fund 9,190,927 sh (+1.69%)
John Paulson 7,182,000 sh (+0.11%)
Bernard Horn 20,689 sh (unchged)
First Eagle Investment 335 sh (unchged)
Chris Davis 2,100 sh (unchged)
Howard Marks Sold Out
John Burbank Sold Out
John Keeley Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 692,942 sh (-2.59%)
Scott Black 38,015 sh (-2.80%)
Ken Fisher 3,185 sh (-11.03%)
Leon Cooperman 811,635 sh (-12.01%)
RS Investment Management 358,388 sh (-13.66%)
Mario Gabelli 31,862 sh (-14.55%)
Larry Robbins 1,523,609 sh (-23.16%)
Dodge & Cox 1,100 sh (-31.29%)
Lee Ainslie 580,418 sh (-60.23%)
» More
Q4 2015

AGN Guru Trades in Q4 2015

David Tepper 150,000 sh (New)
John Hussman 5,000 sh (New)
Jim Simons 206,701 sh (+283.00%)
Daniel Loeb 5,400,000 sh (+47.18%)
Vanguard Health Care Fund 10,962,347 sh (+19.27%)
Mario Gabelli 33,473 sh (+5.06%)
Ken Fisher 3,306 sh (+3.80%)
Chris Davis Sold Out
Dodge & Cox Sold Out
RS Investment Management 352,778 sh (-1.57%)
Private Capital 166,017 sh (-2.12%)
Pioneer Investments 632,600 sh (-8.71%)
Diamond Hill Capital 57,154 sh (-14.43%)
First Eagle Investment 669,995 sh (-59.91%)
Jeremy Grantham 281,993 sh (-65.60%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA928.105.915 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Guru Investment Theses on Allergan PLC

Baron Funds Comments on Allergan - Jan 27, 2016

Allergan plc (NYSE:AGN) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing brand, generic and biosimilar products. Probably best known for its Botox, Allergan has undergone a massive, M&A driven transformation after combinations with Forest Labs ($25 billion) and Actavis ($66 billion) have created a $120 billion behemoth. In the process, the company has upgraded its quality of earnings and diversified away from legacy dermatology and ophthalmology businesses. Our analysis suggested that Allergan’s earnings could rise from about $15/share this year, to about $25/share in five years making it attractive enough to initiate a small position. Late in the fourth quarter, Pfizer made a long speculated cash and stock bid to acquire Allergan at about a 20% premium to its price. So-called “tax inversion” is one of the goals analysts believe Pfizer was after in attempting to acquire Allergan, and various U.S. politicians have spoken out about the need to try and prevent these kinds of transactions. We believe Allergan should do well regardless of whether this deal will go through or not (although, we think that it will) as the stock did not move and continues to trade at about 20% discount to Pfizer’s offer price.



From the Baron Fifth Avenue Growth Fund Fourth Quarter 2015 Letter.



Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Jan 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.



From the Weitz Funds' Research Fund shareholder letter for fourth quarter 2015.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Jan 22, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Oct 27, 2015

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Formerly Actavis, the “new” Allergan is a collection of significant acquisitions over the past 4-5 years, including Watson Pharmaceuticals, Warner Chilcott, Forest Laboratories and legacy Allergan. In late July, Allergan announced the divestiture of its global generics business to Teva for $40.5B, which we believe is a terrific sale price for AGN. Assuming the transaction closes as expected, Allergan should begin calendar 2016 as a pure-play branded pharmaceutical manufacturer with high single digit annual growth prospects and a reloaded balance sheet. We believe the stock is compelling at current prices.



From Wallace Weitz (Trades, Portfolio)'s 3Q 2015 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Allergan PLC

Baron Funds Comments on Allergan Guru stock highlight
Allergan plc (NYSE:AGN) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing brand, generic and biosimilar products. Probably best known for its Botox, Allergan has undergone a massive, M&A driven transformation after combinations with Forest Labs ($25 billion) and Actavis ($66 billion) have created a $120 billion behemoth. In the process, the company has upgraded its quality of earnings and diversified away from legacy dermatology and ophthalmology businesses. Our analysis suggested that Allergan’s earnings could rise from about $15/share this year, to about $25/share in five years making it attractive enough to initiate a small position. Late in the fourth quarter, Pfizer made a long speculated cash and stock bid to acquire Allergan at about a 20% premium to its price. So-called “tax inversion” is one of the goals analysts believe Pfizer was after in attempting to acquire Allergan, and various U.S. politicians have spoken out about the need to try and prevent these kinds of transactions. We believe Allergan should do well regardless of whether this deal will go through or not (although, we think that it will) as the Read more...
Weitz Funds Comments on Allergan Guru stock highlight
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business. Read more...
Wallace Weitz Comments on Allergan Guru stock highlight
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business. Read more...
5 Top Stocks of the Outperforming Vanguard Health Care Fund The fund has beat the index on a one-, five- and 10-year basis and since inception
The Vanguard Health Care Fund (Trades, Portfolio) (VGHCX)’s selection of stocks from a variety of areas within the foreign and domestic health care sector has resulted in a fantastic performance record. Read more...
Lee Ainslie Drastically Reduces Priceline, Allergan Holdings Maverick Capital founder cuts stakes by more than half
Lee Ainslie (Trades, Portfolio), founder and managing partner at Maverick Capital, has drastically reduced his holdings in two companies during the third quarter of 2015. Ainslie sold 301,737 shares in Priceline Group Inc. (NASDAQ:PCLN), and has also reduced his holdings in Allergan PLC (NYSE:AGN), selling 879,142 shares for a 60.23% reduction. Read more...
Valeant Top Shareholder Sequoia Fund's Largest New Buys Outperforming investors in embattled company added 9 stocks in 3rd quarter
Until the Valeant Pharmaceuticals (NYSE:VRX) saga erupted in late October, largest shareholder Sequoia Fund was having, unlike many of its peers, a good year and decade. Read more...
Jeremy Grantham Adds to Stakes in Pharmaceutical Stocks Guru reduces holdings in Amazon, American Express
Jeremy Grantham (Trades, Portfolio) has built a reputation over the years by identifying speculative “bubbles” as they were happening and guiding clients away from them. His third-quarter transactions suggest that the reverse may be happening in pharmaceuticals. Read more...
Wallace Weitz Comments on Allergan Guru stock highlight
Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Formerly Actavis, the “new” Allergan is a collection of significant acquisitions over the past 4-5 years, including Watson Pharmaceuticals, Warner Chilcott, Forest Laboratories and legacy Allergan. In late July, Allergan announced the divestiture of its global generics business to Teva for $40.5B, which we believe is a terrific sale price for AGN. Assuming the transaction closes as expected, Allergan should begin calendar 2016 as a pure-play branded pharmaceutical manufacturer with high single digit annual growth prospects and a reloaded balance sheet. We believe the stock is compelling at current prices. Read more...
Howard Marks' Largest Trades in Second Quarter Guru bought Allergan, dropped his stake in Masonite by 50% and almost sold out Amsurg Corp.
Howard Marks (Trades, Portfolio) has been the chairman of Oaktree Capital Management L.P. since its formation in 1995. He manages a portfolio composed of 68 stocks with a total value of $5.33 billion. Read more...
Lee Ainslie Adds to Stake in Allergan Kansas City Southern, Charter Communications lead list of new stakes in portfolio
Lee Ainslie (Trades, Portfolio), founder and CEO of Dallas-based Maverick Capital Ltd., consults Maverick’s six industry sector heads before reaching conclusions on stocks. Their insights have helped Maverick Capital grow from $38 million when it was founded in 1993 to $10 billion today. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 35.51
AGN's P/E(ttm) is ranked lower than
66% of the 804 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.70 vs. AGN: 35.51 )
Ranked among companies with meaningful P/E(ttm) only.
AGN' s P/E(ttm) Range Over the Past 10 Years
Min: 11.01  Med: 27.00 Max: 485.71
Current: 35.51
11.01
485.71
Forward P/E 14.45
AGN's Forward P/E is ranked higher than
59% of the 409 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.38 vs. AGN: 14.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.56
AGN's P/B is ranked higher than
72% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. AGN: 1.56 )
Ranked among companies with meaningful P/B only.
AGN' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 1.75 Max: 5.9
Current: 1.56
1.03
5.9
P/S 4.80
AGN's P/S is ranked lower than
83% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. AGN: 4.80 )
Ranked among companies with meaningful P/S only.
AGN' s P/S Range Over the Past 10 Years
Min: 0.99  Med: 1.84 Max: 5.82
Current: 4.8
0.99
5.82
PFCF 29.65
AGN's PFCF is ranked higher than
54% of the 481 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.29 vs. AGN: 29.65 )
Ranked among companies with meaningful PFCF only.
AGN' s PFCF Range Over the Past 10 Years
Min: 6.64  Med: 14.18 Max: 39.29
Current: 29.65
6.64
39.29
POCF 25.27
AGN's POCF is ranked lower than
57% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.33 vs. AGN: 25.27 )
Ranked among companies with meaningful POCF only.
AGN' s POCF Range Over the Past 10 Years
Min: 5.97  Med: 11.79 Max: 33.27
Current: 25.27
5.97
33.27
EV-to-EBITDA 59.67
AGN's EV-to-EBITDA is ranked lower than
92% of the 862 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.85 vs. AGN: 59.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 9.70 Max: 105.7
Current: 59.67
-224.1
105.7
Shiller P/E 599.72
AGN's Shiller P/E is ranked lower than
98% of the 177 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.68 vs. AGN: 599.72 )
Ranked among companies with meaningful Shiller P/E only.
AGN' s Shiller P/E Range Over the Past 10 Years
Min: 14.67  Med: 47.12 Max: 817.85
Current: 599.72
14.67
817.85
Current Ratio 2.05
AGN's Current Ratio is ranked lower than
54% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. AGN: 2.05 )
Ranked among companies with meaningful Current Ratio only.
AGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.93 Max: 9.8
Current: 2.05
1.31
9.8
Quick Ratio 1.89
AGN's Quick Ratio is ranked higher than
56% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. AGN: 1.89 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.00 Max: 8.82
Current: 1.89
0.78
8.82
Days Inventory 125.57
AGN's Days Inventory is ranked lower than
54% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. AGN: 125.57 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 108.18  Med: 121.54 Max: 133.19
Current: 125.57
108.18
133.19
Days Sales Outstanding 43.14
AGN's Days Sales Outstanding is ranked higher than
78% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. AGN: 43.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 66.96 Max: 92.81
Current: 43.14
39.05
92.81
Days Payable 29.86
AGN's Days Payable is ranked lower than
86% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. AGN: 29.86 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 26.19  Med: 59.63 Max: 107.57
Current: 29.86
26.19
107.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.09
AGN's Dividend Yield is ranked lower than
99% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. AGN: 0.09 )
Ranked among companies with meaningful Dividend Yield only.
AGN' s Dividend Yield Range Over the Past 10 Years
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.09
0.08
0.63
Yield on cost (5-Year) 0.09
AGN's Yield on cost (5-Year) is ranked lower than
99% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.86 vs. AGN: 0.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AGN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.08  Med: 0.32 Max: 0.63
Current: 0.09
0.08
0.63
3-Year Average Share Buyback Ratio -20.20
AGN's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.90 vs. AGN: -20.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.2  Med: -3.15 Max: 5.5
Current: -20.2
-20.2
5.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.41
AGN's Price/Projected FCF is ranked higher than
68% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.19 vs. AGN: 1.41 )
Ranked among companies with meaningful Price/Projected FCF only.
AGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.14 Max: 3.29
Current: 1.41
0.59
3.29
Price/Median PS Value 2.77
AGN's Price/Median PS Value is ranked lower than
88% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.11 vs. AGN: 2.77 )
Ranked among companies with meaningful Price/Median PS Value only.
AGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.35 Max: 5.39
Current: 2.77
0.67
5.39
Price/Graham Number 2.08
AGN's Price/Graham Number is ranked higher than
50% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. AGN: 2.08 )
Ranked among companies with meaningful Price/Graham Number only.
AGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.54  Med: 2.58 Max: 21.63
Current: 2.08
1.54
21.63
Earnings Yield (Greenblatt) (%) -1.78
AGN's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AGN: -1.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.82  Med: 6.30 Max: 12.3
Current: -1.78
-1.82
12.3
Forward Rate of Return (Yacktman) (%) 8.28
AGN's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. AGN: 8.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AGN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.1  Med: 8.00 Max: 16.1
Current: 8.28
-3.1
16.1

More Statistics

Revenue(Mil) $22817
EPS $ 7.61
Beta1.39
Short Percentage of Float1.24%
52-Week Range $237.50 - 340.34
Shares Outstanding(Mil)394.12

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 18,240 17,714 19,367 21,148
EPS($) 15.49 16.63 19.40 22.00
EPS without NRI($) 15.49 16.63 19.40 22.00

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, FRX, MRX, ESALF » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Allergan PLC, formerly known as Actavis PLC was incorporated in Ireland on May 16, 2013. It is an integrated specialty pharmaceutical company. The Company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments, Pharma, Specialty Brands and Anda Distribution. The Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the Company to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. It competes with generic manufacturers of pharmaceutical products. It is subject to extensive, complex and evolving regulation by the federal government, the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for AGN

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Sells Stake in Humana Feb 03 2016 
Bill Ackman’s Fund Falls by Double Digits Again in January Feb 02 2016 
Baron Funds Comments on Allergan Jan 27 2016 
Bill Ackman's Pershing Square Annual Investor Letter Jan 27 2016 
Dalio, Tepper, Klarman Ranked Best Hedge Fund Managers Jan 26 2016 
Weitz Funds Comments on Allergan Jan 25 2016 
Wallace Weitz Comments on Allergan Jan 22 2016 
2 Stocks Super Investors Are Buying in Large Quantities Dec 26 2015 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
5 Guru Picks in Volatile Biotech Industry Dec 23 2015 

More From Other Websites
Loeb's Allergan Stake Grows by 50% Feb 12 2016
ALLERGAN PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Feb 12 2016
Dan Loeb's Q4 trades Feb 12 2016
Five Foreign Stocks Hedge Funds Love Feb 12 2016
Inside the M&A Deals in the Health-Care Sector Feb 12 2016
Eli Lilly loses latest round in UK drug patent battle Feb 12 2016
Eli Lilly loses latest round in UK drug patent battle Feb 12 2016
Napier Park is Betting Big on Media General (MEG) and Allergan (AGN) for 2016; Plus 3 Other Major... Feb 11 2016
3 Value Stocks Ready to Outperform Feb 10 2016
Allergan to Present at the RBC Capital Markets Healthcare Conference Feb 10 2016
Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan) Feb 09 2016
[$$] Pfizer seeks to soothe fears over R&D Feb 09 2016
Pfizer To Reorganize After Allergan Buyout, With Saunders President Feb 08 2016
Pfizer unveils management line up for combined company Feb 08 2016
Pfizer unveils management line up for combined company Feb 08 2016
[$$] Pfizer Outlines Post-Merger Management Slate Feb 08 2016
Pfizer Names New Executives to Run Units After Allergan Deal Feb 08 2016
Pfizer to create operating unit after Allergan deal closes Feb 08 2016
Pfizer Names Executive Leadership Team for Combined Organization Upon Close of Proposed Allergan... Feb 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK